| Previous Close | 0.1150 |
| Open | 0.0000 |
| Bid | 0.115 x 0 |
| Ask | 0.125 x 0 |
| Day's Range | 0.0000 - 0.0000 |
| 52 Week Range | |
| Volume | 0 |
| Avg. Volume | 381,956 |
| Market Cap | 9.623M |
| Beta (3Y Monthly) | -0.84 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.268 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
VANCOUVER, British Columbia, Nov. 14, 2018 -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that it has.
CTL-X is a unique cannabis strain mix which has so far demonstrated evidence of reducing acute pain. CTL-X is the culmination of two years of preclinical testing by the Company’s research arm, Cannevert Therapeutics Ltd. (“Cannevert”), located at the University of British Columbia.
VANCOUVER, British Columbia, Nov. 06, 2018 -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce the Closing of.
The investment is by way of acquiring shares in a holding company (“Holdco”) which has a long-term lease in an acreage in Kelowna which could accommodate up to 10 additional 10,000 square foot cannabis growing facilities. The total investment into the first building is $5,000,000.
CannX is a meeting of global leaders in all areas of medical cannabis where the latest scientific and clinical research, agricultural practices, innovation, and business opportunities are explored. Israel has been one of the world's leading countries for medical cannabis research.
The Masterclass Medicinal Cannabis® is an exclusive education seminar hosted by Dr. Arno Hazekamp, the former Head of Research and Education for Bedrocan BV, a multinational company that has been growing and supplying pharmaceutical grade medicinal cannabis since the early 1980s. Since its start in 2011, the Masterclass has provided a one week intensive and in-depth learning environment focused on providing science-based information on all aspects of cannabis as a plant-based medicine.
VANCOUVER, B.C., Oct. 05, 2018 -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce along with the Institute.
Under the terms of the MOU, both companies wish to collaborate in a structured, scientific manner with respect to formally identifying and cooperating on the advancement of medical cannabis strains or cultivars as well as to jointly develop, commercialize and patent protect medicinal products to treat specific diseases and chronic conditions. Veritas’ CEO, Dr. Lui Franciosi stated, “With Agrima’s superior breeding and cultivating practices, our scientists at Cannevert Therapeutics Ltd. (“CTL”) will be able to further research for both companies by infusing CTL’s pharmacological knowledge and practices in discovering and developing proprietary products that have consistent and optimal clinical effects. This will be a great partnership for the science and business of medical cannabis”.
VANCOUVER, British Columbia, Sept. 19, 2018-- Veritas Pharma Inc. is pleased to provide a corporate update on its activities, milestones over the first three quarters of 2018, and strategies for growth ...